| Literature DB >> 28441960 |
Fiona Maas1, Suzanne Arends2,3, Elisabeth Brouwer2, Hendrika Bootsma2, Reinhard Bos3, Freke R Wink3, Anneke Spoorenberg2,3.
Abstract
BACKGROUND: To aim was to investigate the additional value of incorporating the de Vlam cervical facet joint score in the modified ankylosing spondylitis (AS) spine score (mSASSS) for the evaluation of spinal radiographic outcome in AS.Entities:
Keywords: Ankylosing spondylitis; OMERACT; Outcome measure; Radiography; Spinal damage
Mesh:
Substances:
Year: 2017 PMID: 28441960 PMCID: PMC5405528 DOI: 10.1186/s13075-017-1285-1
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Baseline characteristics of the AS study population
| All patients | Patients with available CASSS | |
|---|---|---|
| n = 98 | n = 89 | |
| Male gender | 74 (76) | 66 (74) |
| Age (years) | 41.8 ± 11.2 | 41.0 ± 11.1 |
| Symptom duration (years) | 16 (7–24) | 16 (7–24) |
| Time since diagnosis (years) | 7 (2–15) | 7 (2–16) |
| HLA-B27+ | 82 (84) | 74 (83) |
| BMI (kg/m2) | 26.1 ± 3.5 | 25.4 ± 3.0 |
| Current smoker | 30 (37) | 28 (38) |
| Total smoking duration (years) | 12 (0–25) | 12 (0–24) |
| History of IBD | 9 (9) | 9 (10) |
| History of uveitis | 27 (28) | 25 (28) |
| History of psoriasis | 11 (11) | 11 (12) |
| Peripheral arthritis | 21 (21) | 18 (20) |
| NSAID use | 79 (85) | 72 (85) |
| DMARD use | 23 (23) | 23 (26) |
| BASDAI (0–10) | 5.9 ± 1.6 | 5.8 ± 1.7 |
| ASDASCRP | 3.8 ± 0.8 | 3.8 ± 0.8 |
| CRP (mg/L) | 15 (7–25) | 15 (7–25) |
| Occiput-to-wall distance (cm) | 5.0 (0.0–11.1) | 4.5 (0.0–10.0) |
| Lateral spinal flexion (cm) | 7.9 (5.0–11.5) | 8.1 (5.5–11.7) |
| Modified Schober test (cm) | 3.0 (1.2–4.0) | 4.5 (0.0–10.0) |
| Chest expansion (cm) | 3.0 (2.0–4.0) | 3.0 (2.0–4.0) |
| BASFI (0–10) | 5.6 (3.7–7.1) | 5.5 (3.6–7.1) |
| ASQoL (0–18) | 10 (7–13) | 9 (7–12) |
Values are presented as number of patients (%), mean ± SD, or median (IQR). Total smoking duration: current and past smoking. Peripheral arthritis: presence of ≥1 swollen joints (range 0–44). AS ankylosing spondylitis, CASSS combined AS spine score, HLA human leukocyte antigen, BMI body mass index, NSAID non-steroidal anti-inflammatory drug, DMARD disease-modifying antirheumatic drug, BASDAI bath AS disease activity index, ASDAS AS disease activity score, GDA global disease activity, CRP, C-reactive protein, BASFI bath AS functional index, ASQoL AS quality of life questionnaire
Fig. 1Bland and Altman plots show differences between readers in progression scores in assessed using the modified Stoke ankylosing spondylitis spine score (mSASSS) (a) and the combined ankylosing spondylitis spine score (CASSS) (b), plotted against the average scores of both readers and the 95% limits of agreement (+/− 1.96*SD)
Status and progression scores and proportion of patients with damage and progression according to the mSASSS and the composite CASSS
| mSASSS (range 0–72) | CASSS (range 0–87) | |
|---|---|---|
| Status scores | ||
| Observed range | 0–72 | 0–87 |
| Mean ± SD | 19.3 ± 18.7 | 21.8 ± 21.3 |
| Median (IQR) | 11.3 (5.1–29.9) | 13.5 (5.4–36.6) |
| Definite damage | 51 (57) | 54 (61) |
| Maximum score | 3 (3) | 1 (1) |
| Progression scores | ||
| Observed range | −3.5–20.8 | −4.3–20.8 |
| Mean ± SD | 2.7 ± 4.6 | 3.0 ± 4.8 |
| Median (IQR) | 1.2 (0.0–3.6) | 1.6 (0.0–4.2) |
| SDC | 1.8 | 1.9 |
| SRM | 0.59 | 0.63 |
| Progression >0 | 64 (72) | 64 (72) |
| Progression ≥ SDC | 40 (45) | 41 (46) |
| Definite progression | 43 (48) | 49 (55) |
Values are presented as mean ± SD, median (IQR), or number of patients (%). mSASSS modified stoke ankylosing spondylitis spine score, CASSS combined ankylosing spondylitis spine score, SDC smallest detectable change, SRM standardized response mean
Fig. 2Differences in status and progression scores when comparing the composite score (combined ankylosing spondylitis spine score (CASSS)) (range 0–87) with modified Stoke ankylosing spondylitis spine score (mSASSS) (range 0–72). X-axis mSASSS status scores at baseline (a) and progression scores during 4 years of follow-up (b). Y-axis: differences between mSASSS and CASSS status and progression scores
Correlation between radiographic damage assessed using the mSASSS and CASSS and spinal mobility, physical function, and quality of life at baseline
| mSASSS | CASSS | |
|---|---|---|
| Cervical rotationa | −0.56** | −0.63** |
| Occiput-to-wall distance | 0.64** | 0.67** |
| Lateral spinal flexion | −0.62** | −0.61** |
| Modified Schober test | −0.44** | −0.45** |
| Chest expansion | −0.33** | −0.35** |
| BASFI | 0.24* | 0.26* |
| ASQoL | 0.03 | −0.01 |
Correlation is expressed as Spearman’s rho. aAnalysis performed with 4 years of data. mSASSS modified stoke ankylosing spondylitis spine score, CASSS combined ankylosing spondylitis spine score, BASFI Bath ankylosing spondylitis functional index, ASQoL ankylosing spondylitis quality of life questionnaire. *Statistically significant correlation p ≤ 0.05. **Statistically significant correlation p ≤ 0.01